Advertisement

Topics

Blogs about Biotechnology, Pharmaceutical and Healthcare

03:58 EDT 26th April 2017 | BioPortfolio

Read the latest opinions - blogs from pharmaceutical and life science industry experts.

Showing News Articles 1–25 of 97,000+

Tuesday 25th April 2017

First-Ever Dementia Innovation Readiness Index launched at ADI Conference

26 April 2017 – The first-ever Dementia Innovation Readiness Index has been launched by the Global Coalition on Aging and Alzheimer’s Disease International (ADI) during a special pre-conference session at the 32nd International Conference of ADI in Kyoto, Japan. The index provides a comprehensive evaluation of existing and possible approaches and processes that have an impact on the p...

Dogs Get Their Very Own Family Tree

First came working dogs — breeds that could guard or herd livestock. Later came the hunting dogs. Last came the cute, fluffy things.

FDA Takes Action Against Fraudulent Cancer Products

By: Donald D. Ashley, J.D., and Douglas Stearn, J.D. A cancer diagnosis often provokes a sense of desperation. Unfortunately, rogue operations exploiting those fears peddle untested and potentially dangerous products, particularly on the internet. FDA responds in two ways: with … Continue reading →

The Voice of the Patient

Did you ever wonder what is is like having lung cancer?  Or narcolepsy?    What factors are most important to patients when receiving treatment for these diseases? The FDA is working to collect these answers to help guide their drug approval process.  The FDA’s “Voice of the Patient” aims to “…more systematically gather patients’ perspectives […]

You Thought It Was An Urgent Care Center, Until You Got The Bill

Patients are confusing free-standing emergency rooms with urgent care centers, and paying a price.

DOJ Asks for More Time to Mull Religious Exemption to Contraception Coverage

Is the Trump administration reneging on Donald Trump's campaign promise to exempt religious organizations from having to provide birth control?

DG Investors Should Consider AbbieVie Now That It Has Made The CCC List

Roll-Up Isn't Dead

Why Mylan, Perrigo and Endo Won't Be Playing Spoiler in Akorn-Fresenius Tie Up

Click to view a price quote on FSNUY.

Atara enters trial collaboration with Merck for EBV-related cancer

Atara Biotherapeutics Inc. and Merck & Co. Inc. entered a trial collaboration to study the combination of Atara’s ATA129 with Merck’s Keytruda (pembrolizumab) as a potential treatment for nasopharyngeal carcinoma (NPC).

Biohaven licenses Catalent's Zydis technology for BHV0223; deal revealed to be worth up to $1.9bn

Portage Biotech Inc.'s Biohaven Pharmaceuticals Holding Co. Ltd. was granted an exclusive worldwide license to use Catalent's Zydis fast-dissolving technology in the development of Biohaven's BHV0223 (riluzole).

Becton Dickinson to acquire Bard for $23.5bn

Becton Dickinson & Co. agreed to acquire CR Bard Inc. (medtech focused on vascular, urology, and oncology) for $317 per common share (27% premium), or $23.5bn in cash and stock including net debt.

Fresenius Kabi to acquire Rx and OTC company Akorn for $4.7bn

Akorn Inc. (branded, generic and OTC pharmaceuticals) agreed to be acquired by global health care company Fresenius Kabi AG for $34 per share (41% premium to ten day average prior to date of first discussion) in cash or $4.3bn, plus the assumption of $450mm in debt.

Molecular diagnostics company AltheaDx raises $27mm in Series D financing

AltheaDx Inc. (molecular diagnostics/personalized medicine) raised $27mm in its Series D round from undisclosed investors. The company will use the funds to expand its salesforce and marketing efforts. AltheaDx recently completed a pivotal double-blinded, randomized, controlled neuropsychiatric clinical trial and is awaiting a local Medicare coverage determination. The company is also in discussio...

Theraclion and Furui create joint venture to market Echopulse in China

Theraclion SAS and Inner Mongolia Furui Medical Science Co. Ltd. agreed to create a joint venture named Theraclion China Co. Ltd. to market Theraclion’s Echopulse therapeutic ultrasound device in China.

Macrocyclic peptide company Circle Pharma raises $6.5mm in Series A financing

Circle Pharma Inc. secured Series A funding led by returning backers Pfizer, Mission Bay Capital, and ShangPharma Investment Group along with a syndicated group of individual investors. In an expansion of the round, WI Harper Group (also adds a board seat), Elements Partners, LLC, Whitesun Healthcare Ventures Limited and LifeForce Capital joined the financing, bringing the total Series A proceeds...

Two Pore Guys closes $24.5mm Series A

Two Pore Guys Inc. raised $24.5mm in its Series A financing led by Khosla Ventures.

Investors put $10mm into Leap Therapeutics concurrent with Macrocure merger

Concurrent with the closing of the merger between Macrocure Ltd. and Leap Therapeutics Inc., existing Leap investor HealthCare Ventures purchased 1.01mm Leap shares at $9.90, for gross proceeds of $10mm. Following the acquisition, the combined entity is taking the Leap name.

Forge closes $15mm Series A

Antibiotics developer Forge Therapeutics Inc. raised $15mm through a Series A financing led by MagnaSci Ventures, which adds a board member and was joined by Evotec AG, Alexandria Venture Investments, MP Healthcare Venture Management, Red Apple Group, and WS Investments.

Leap Therapeutics and Macrocure merge

Private immuno-oncology company Leap Therapeutics Inc. and public Israeli firm Macrocure Ltd. (developed an injectable cell therapy for wound care) have agreed to merge. The combined entity will operate as Leap Therapeutics, take over Macrocure's listing on the Nasdaq Global Market, and will continue to develop Leap's pipeline of cancer therapeutics.

Onconova nets $4.85mm through public stock offering

Onconova Therapeutics Inc. netted $4.85mm through a public offering of 2.48mm common shares at $2.10. The company is developing treatments for myelodysplastic syndromes, and will use the offering proceeds to support ongoing trials of lead candidate rigosertib for higher risk MDS.

Adamis nets $14.1mm via FOPO

Adamis Pharmaceuticals Corp., which is developing therapies for respiratory diseases and allergy, netted $14.1mm through the follow on public offering of 4.3mm common shares as $3.50 each.

Top Authors, by 5 years of e-Views, 4/25/2017, on pharmaceuticalintelligence.com

Top Authors, by 5 years of e-Views, 4/25/2017, on pharmaceuticalintelligence.com Reporter: Aviva Lev-Ari, PhD, RN   Top Authors for all days ending 2017-04-25 (Summarized) All Time 4/30/2012 – 4/25/2017 Author Views Aviva Lev-Ari, PhD, RN 315,262   Larry H Bernnstein, MD, FCAP 220,787 Tilda Barliya, PhD 47,008   Stephen J Williams, PhD 39,704 Dror Nir, […]

Forge Therapeutics Raises $15M to Take on Drug-Resistant Superbugs

One reason that drug-resistant “superbugs” are a growing healthcare problem is the hardiness of gram-negative bacteria, a type of bacteria whose characteristics render many antibiotics ineffective. Forge Therapeutics says it has found a way to target an enzyme found only in these bacteria, and potentially take them out. Now, the biotech firm is preparing to […]

Beware of 'Natural' Cancer Cures That Could Harm, FDA Warns

The FDA is warning 14 companies to stop making bogus cancer cure claims and is warning consumers not to buy into the quackery.


Quick Search
Advertisement